Fresenius Kabi SwissBioSim GmbH

6 in Phase 3

Quick facts

Phase 3 pipeline

EU-approved RoActemra · Immunology
RoActemra (tocilizumab) is a humanized monoclonal antibody that blocks the interleukin-6 (IL-6) receptor, reducing inflammatory signaling in immune-mediated diseases.
EU-Humira
FKS518 · Immunology
FKS518 is a calcineurin inhibitor that suppresses T-cell activation by blocking the phosphatase calcineurin, thereby reducing immune-mediated rejection.
MSB11022 · Oncology
MSB11022 is a biosimilar of trastuzumab that targets HER2-positive cancer cells by binding to the HER2 receptor and inhibiting tumor growth.
MSB11456 · Oncology
MSB11456 is a biosimilar of trastuzumab that targets HER2-positive cancer cells by binding to the HER2 receptor and blocking growth signaling.
US-licensed Prolia (Amgen) · Osteoporosis
Prolia is a human monoclonal antibody that targets RANKL, a protein involved in bone resorption.

Phase 1 pipeline

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about Fresenius Kabi SwissBioSim GmbH

What is Fresenius Kabi SwissBioSim GmbH's pipeline?

Fresenius Kabi SwissBioSim GmbH has 6 drugs in Phase 3, 0 in Phase 2, 2 in Phase 1. Late-stage candidates include EU-approved RoActemra, EU-Humira, FKS518, MSB11022.

Sector hub: All tracked pharma companies